You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 14, 2024

CLINICAL TRIALS PROFILE FOR PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Pantoprazole Sodium In 0.9% Sodium Chloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00141817 ↗ Study Evaluating Pantoprazole in Children With GERD Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 2005-08-01 The purpose of this study is to characterize the PK profile, safety and tolerability of single and multiple doses of pantoprazole in children aged 1 through 11 years with endoscopically proven GERD.
NCT00259012 ↗ Study Evaluating Pantoprazole Sodium Enteric-Coated Spheroid Suspension In Infants With Presumed GERD Completed Nycomed Phase 3 2005-11-01 The purpose of this study is to characterize the pharmacokinetic (PK) and pharmacodynamic (PD) profiles to determine the safety and tolerability of single and multiple doses of pantoprazole in infants aged 1 through 11 months.
NCT00259012 ↗ Study Evaluating Pantoprazole Sodium Enteric-Coated Spheroid Suspension In Infants With Presumed GERD Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 2005-11-01 The purpose of this study is to characterize the pharmacokinetic (PK) and pharmacodynamic (PD) profiles to determine the safety and tolerability of single and multiple doses of pantoprazole in infants aged 1 through 11 months.
NCT00300755 ↗ Study Evaluating Pantoprazole in Children With Gastroesophageal Reflux Disease (GERD) Completed Nycomed Phase 3 2006-05-01 To evaluate the clinical outcomes of treatment with oral pantoprazole in children 1 through 5 years of age with endoscopically proven symptomatic GERD.
NCT00300755 ↗ Study Evaluating Pantoprazole in Children With Gastroesophageal Reflux Disease (GERD) Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 2006-05-01 To evaluate the clinical outcomes of treatment with oral pantoprazole in children 1 through 5 years of age with endoscopically proven symptomatic GERD.
NCT00312806 ↗ Effect of Pantoprazole on the Symptoms of Acid Reflux Disease in Adult Patients (BY1023/M3-341) Completed Takeda Phase 3 2006-05-01 The aim of the present study is to identify factors (such as symptom patterns and symptom scores) that influence the response to treatment with pantoprazole using different evaluation methods (e.g., ReQuestâ„¢ questionnaire, patient and investigator assessment). Pantoprazole will be administered once daily in the morning at one dose level. The study duration consists of a treatment period of 8 weeks. The study will provide further data on safety and tolerability of pantoprazole.
NCT00365300 ↗ Study Evaluating the Efficacy and Safety of Pantoprazole in Infants With Symptomatic Gastroesophageal Reflux Disease (GERD) Completed Wyeth is now a wholly owned subsidiary of Pfizer Phase 3 2006-09-01 To assess the efficacy of pantoprazole for the treatment of infants with symptomatic Gastroesophageal Reflux Disease (GERD).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Pantoprazole Sodium In 0.9% Sodium Chloride

Condition Name

Condition Name for Pantoprazole Sodium In 0.9% Sodium Chloride
Intervention Trials
Gastroesophageal Reflux 7
Healthy 7
Postperfusion Syndrome 1
Drug Interactions 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Pantoprazole Sodium In 0.9% Sodium Chloride
Intervention Trials
Gastroesophageal Reflux 8
Esophagitis, Peptic 5
Malnutrition 3
Ulcer 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Pantoprazole Sodium In 0.9% Sodium Chloride

Trials by Country

Trials by Country for Pantoprazole Sodium In 0.9% Sodium Chloride
Location Trials
United States 111
Canada 10
India 7
Germany 4
South Africa 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Pantoprazole Sodium In 0.9% Sodium Chloride
Location Trials
Texas 7
Kentucky 6
New York 5
Illinois 5
Florida 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Pantoprazole Sodium In 0.9% Sodium Chloride

Clinical Trial Phase

Clinical Trial Phase for Pantoprazole Sodium In 0.9% Sodium Chloride
Clinical Trial Phase Trials
Phase 4 2
Phase 3 8
Phase 2 1
[disabled in preview] 12
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Pantoprazole Sodium In 0.9% Sodium Chloride
Clinical Trial Phase Trials
Completed 21
Unknown status 1
Not yet recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Pantoprazole Sodium In 0.9% Sodium Chloride

Sponsor Name

Sponsor Name for Pantoprazole Sodium In 0.9% Sodium Chloride
Sponsor Trials
Wyeth is now a wholly owned subsidiary of Pfizer 7
Nycomed 2
Teva Pharmaceuticals USA 2
[disabled in preview] 7
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Pantoprazole Sodium In 0.9% Sodium Chloride
Sponsor Trials
Industry 22
Other 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.